Not Yet RecruitingNot Applicable

Study on Biomarkers of Immune-Related Adverse Events

440 participantsStarted 2026-04

Plain-language summary

1. To identify biomarkers of immune-related adverse events; 2. To develop a predictive model for immune-related adverse events.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age \>18 years;
✓. Karnofsky Performance Status (KPS) \>60;
✓. Expected to receive at least one cycle of immune checkpoint inhibitor therapy;
✓. Expected survival \>6 months.

✕. Prior treatment with immune checkpoint inhibitors;
✕. Active autoimmune diseases (including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, scleroderma, etc.);
✕. Use of systemic immunosuppressive agents within 14 days prior to enrollment (prednisone \>10 mg/day or equivalent);
✕. Inability to provide biological samples.

Immune-Related Adverse Events

Timeframe: 2 years

NCT IDNCT07527585

SponsorHuazhong University of Science and Technology

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2032-12

Lingyan Xiao